Business Context and Reporting Period
This Form 8-K is a current report filed by Matinas BioPharma Holdings, Inc. on March 13, 2025. The report discloses a corporate governance event regarding the departure of a director and officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
Departure of Directors and Officers:
- Eric Ende resigned as a member of the Board of Directors and as Chairman of the Board.
- The resignation is effective March 14, 2025.
- The stated reason for the resignation is Mr. Ende's other professional obligations.
- The Company explicitly states that the resignation was not the result of a material disagreement or change in the Company's direction.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future operations, or new risk factors. The only contingency noted is the leadership transition, which the Company characterizes as non-contentious.
Investor Verification Checklist
- Verify the effective date of Eric Ende's resignation (March 14, 2025).
- Confirm whether a successor Chairman or Board member has been appointed to fill the vacancy.
- Review subsequent filings for any impact on the Company's strategic direction or board composition.
- Note that no financial metrics are disclosed in this specific filing.